To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
Patients are randomized to receive six single escalating doses of 524W91 or placebo, with each dose separated by at least a 6-day washout interval. In the time between 2 of the doses, the effect of food on pharmacokinetics will be investigated, with one dose administered in conjunction with a high-fat meal and one dose administered in a fasted state.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
18
ViRx Inc
San Francisco, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.